Global Antifungal Pharmacoeconomic Analysis
This analysis compares antifungal treatments (voriconazole, caspofungin, and LAmB) across multiple countries, assessing cost-effectiveness in hematology/oncology patients.
Key Study Findings by Country
(2009) Australia - Voriconazole vs LAmB (CEA): Hematology/oncology patients (AML, chemotherapy/HSCT). LAmB net cost saving AU$1422/patient.
(2009) Australia - Caspofungin vs LAmB (CMA): Caspofungin net cost saving AU$7245/patient.
(2012) Australia - Caspofungin vs voriconazole (CMA): Caspofungin net cost saving AU$798/patient.
(2007) UK - Caspofungin vs LAmB (CUA): Caspofungin saved GBP£2033/patient + 0.40 QALYs.
(2007) USA - Voriconazole vs LAmB (CMA): 27% reduced cost with voriconazole (US$14950 vs US$20591).
(2008) Germany - Caspofungin vs LAmB (CMA): €298 extra cost/patient with LAmB, worse renal outcomes.
(2008) Italy - Caspofungin vs LAmB (CUA): €3470 saved/patient + 0.25 QALYs with caspofungin.
(2007) USA - Caspofungin vs LAmB (CMA): US$5326 less with caspofungin, better renal outcomes.
(2011) Sweden - Caspofungin vs LAmB (CUA): SEK38,080 saved + 0.25 QALYs with caspofungin.
(2008) Spain - Multi-drug comparison (CEA): Voriconazole showed €144,794 net saving vs alternatives.
(2007) USA - Voriconazole vs LAmB (CEA): US$2551 saved/episode with voriconazole.
Conclusion
This multinational analysis demonstrates significant cost variations between antifungal regimens, with consistent savings for newer agents (voriconazole, caspofungin) versus LAmB across healthcare systems.
No comments:
Post a Comment